Core Viewpoint - The company Guichuang Tongqiao (02190.HK) has entered into an agreement to acquire a 49% stake in E-Med Solutions for approximately €18.375 million (around RMB 149 million), with options to acquire the remaining shares in the future [1][2]. Group 1: Acquisition Details - The acquisition agreement was signed on January 16, 2026, with the company acting as the buyer and E-Med Solutions as the seller [1]. - The total consideration for the acquisition is subject to further adjustments [1]. - The target company, Optimed Holding GmbH, is a limited liability company established under German law and is currently wholly owned by the seller [2]. Group 2: Target Company Overview - Optimed Holding GmbH and its subsidiaries, including Optimed Medizinische Instrumente GmbH, focus on the development, manufacturing, and distribution of medical technology products and solutions [2]. - The main operating subsidiary, Optimed Medizinische Instrumente GmbH, is headquartered in Germany and specializes in high-quality medical products for minimally invasive vascular and urological instruments [2]. - Optimed has a comprehensive product portfolio in the peripheral venous stent market, including devices for the iliac vein, iliac artery bifurcation, inferior vena cava, and aorta [2]. Group 3: Strategic Implications - Following the completion of the acquisition, the company and the target company will integrate their commercialization platforms, including sales and marketing networks, promotional capabilities, and customer service infrastructure [2]. - The target company will serve as the exclusive distributor for all vascular products outside of mainland China [2]. - Rüdiger Hausherr will continue as CEO of Optimed and report to Dr. Zhao Zhong, the company's chairman and CEO, which is expected to enhance and accelerate the company's international sales capabilities and global expansion [2].
归创通桥(02190.HK)拟收购德国Optimed Holding 49%股权 加速全球市场扩张